Literature DB >> 106914

Gentamicin- and silver-resistant pseudomonas in a burns unit.

K Bridges, A Kidson, E J Lowbury, M D Wilkins.   

Abstract

In 1977-8 gentamicin-resistant strains of Pseudomonas aeruginosa became very common in a burns unit, over 90% being resistant at the peak of the outbreak. Some strains were also resistant to silver nitrate, though silver resistance was not found in any other strains of Ps aeruginosa isolated. Unlike the gentamicin resistance, the silver resistance was unstable, and strains became sensitive on repeated subculture. All the gentamicin-resistant strains of Ps aeruginosa were of the same serotype (O:11, H:2,5). Though gentamicin resistance could be transferred in vitro from resistant strains of Ps aeruginosa to one sensitive strain of Ps aeruginosa, there was no evidence of in-vivo transfer of gentamicin resistance between strains of pseudomonas in the patients' burns, nor was there evidence of transfer of gentamicin resistance between Ps aeruginosa and enterobacteria. Carbenicillin-resistant and gentamicin-resistant Ps aeruginosa were sometimes found in the same burns, but no gentamicin-carbenicillin (doubly) resistant strains were found among the 986 strains tested during the outbreak. The outbreak of gentamicin-resistant Ps aeruginosa from burns was not reduced by stopping treatment with gentamicin and its analogues but only by segregating all patients with Ps aeruginosa in one of the two wards of the unit and admitting new patients only to the other ward.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 106914      PMCID: PMC1597731          DOI: 10.1136/bmj.1.6161.446

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  9 in total

1.  [Transferable resistance to gentamicin. II. Transmission and linkage of the resistance character].

Authors:  J L Witchitz; Y A Chabbert
Journal:  Ann Inst Pasteur (Paris)       Date:  1972-03

2.  Clearance from a hospital of gram-negative bacilli that transfer carbenicillin-resistance to Pseudomonas aeruginosa.

Authors:  E J Lowbury; J R Babb; E Roe
Journal:  Lancet       Date:  1972-11-04       Impact factor: 79.321

3.  Transfer of anibioic resistanceetween Pseudomonas aeruginosa, Escherichia coli, and other gram-negative bacilli in rns.

Authors:  E Roe; R J Jones; E J Lowbury
Journal:  Lancet       Date:  1971-01-23       Impact factor: 79.321

4.  Alternative forms of local treatment for burns.

Authors:  E J Lowbury; H A Lilly; J S Cason; D M Jackson; J P Bull; J W Davies; P M Ford
Journal:  Lancet       Date:  1971-11-20       Impact factor: 79.321

5.  Sensitivity of Pseudomonas aeruginosa to antibiotics: emergence of strains highly resistant to carbenicillin.

Authors:  E J Lowbury; H A Lilly; A Kidson; G A Ayliffe; R J Jones
Journal:  Lancet       Date:  1969-08-30       Impact factor: 79.321

6.  Antiseptic and aseptic prophylaxis for burns: use of silver nitrate and of isolators.

Authors:  J S Cason; D M Jackson; E J Lowbury; C R Ricketts
Journal:  Br Med J       Date:  1966-11-26

7.  Changes in antibiotic sensitivity patterns of Gram-negative bacilli in burns.

Authors:  E Roe; E J Lowbury
Journal:  J Clin Pathol       Date:  1972-02       Impact factor: 3.411

8.  Drug resistance in relation to use of silver sulphadiazine cream in a burns unit.

Authors:  K Bridges; E J Lowbury
Journal:  J Clin Pathol       Date:  1977-02       Impact factor: 3.411

9.  Gram-negative bacilli in burns.

Authors:  B Davis; H A Lilly; E J Lowbury
Journal:  J Clin Pathol       Date:  1969-11       Impact factor: 3.411

  9 in total
  18 in total

1.  The effect on peritoneal dialysis pathogens of changing topical antibiotic prophylaxis.

Authors:  Dwayne A Pierce; John C Williamson; Vicki S Mauck; Gregory B Russell; Elizabeth Palavecino; John M Burkart
Journal:  Perit Dial Int       Date:  2012-02-01       Impact factor: 1.756

2.  Heavy metal resistance in clinical isolates of Pseudomonas aeruginosa.

Authors:  R Vasishta; S Chhibber; M Saxena
Journal:  Folia Microbiol (Praha)       Date:  1989       Impact factor: 2.099

3.  Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone.

Authors:  Jean-Paul Pirnay; Daniel De Vos; Christel Cochez; Florence Bilocq; Jean Pirson; Marc Struelens; Luc Duinslaeger; Pierre Cornelis; Martin Zizi; Alain Vanderkelen
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

4.  Plasmid-determined silver resistance in Pseudomonas stutzeri isolated from a silver mine.

Authors:  C Haefeli; C Franklin; K Hardy
Journal:  J Bacteriol       Date:  1984-04       Impact factor: 3.490

5.  Influence of laboratory reports on prescribing of antimicrobials for urinary tract infection.

Authors:  M P Barnes
Journal:  J Clin Pathol       Date:  1980-05       Impact factor: 3.411

6.  Shell crosslinked nanoparticles carrying silver antimicrobials as therapeutics.

Authors:  Yali Li; Khadijah Hindi; Kristin M Watts; Jane B Taylor; Ke Zhang; Zicheng Li; David A Hunstad; Carolyn L Cannon; Wiley J Youngs; Karen L Wooley
Journal:  Chem Commun (Camb)       Date:  2009-11-09       Impact factor: 6.222

Review 7.  Silver as biocides in burn and wound dressings and bacterial resistance to silver compounds.

Authors:  Simon Silver; Le T Phung; Gregg Silver
Journal:  J Ind Microbiol Biotechnol       Date:  2006-05-25       Impact factor: 3.346

Review 8.  Nanofibers offer alternative ways to the treatment of skin infections.

Authors:  T D J Heunis; L M T Dicks
Journal:  J Biomed Biotechnol       Date:  2010-07-28

9.  Subtractive hybridization yields a silver resistance determinant unique to nosocomial pathogens in the Enterobacter cloacae complex.

Authors:  Anita N Kremer; Harald Hoffmann
Journal:  J Clin Microbiol       Date:  2012-07-25       Impact factor: 5.948

10.  Pyocyanin production by Pseudomonas aeruginosa confers resistance to ionic silver.

Authors:  Michael Muller; Neil D Merrett
Journal:  Antimicrob Agents Chemother       Date:  2014-07-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.